Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Putting The Arch Puzzle Pieces Together

<< Previous

Bullboard Posts

Next >>

Comment by 2019champson Oct 13, 2021 11:11am

116 Views

Post# 34001003

RE:RE:Putting The Arch Puzzle Pieces Together

The drug can benefit many people. It really targets an unmet area. Yes the fda and pharma are corrupt for the most part, but they love money and want to make lots of it. This is a great candidate for a buy out / takeover. Take a look at this list of buyouts / takeovers over the last several years: https://biopharmguy.com/links/company-by-name-defunct.php That's a big list. We will be fine.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario